ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma.
Abstract readClinical Trial, Phase I
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it.
- An update of predictive biomarkers related to WEE1 inhibition in cancer therapy.Journal of cancer research and clinical oncology · 2024Pooled it
- Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.JCO precision oncology · 2026Trial
- Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer.EMBO molecular medicine · 2026Article
- Therapeutic scheduling of WEE1 inhibition preserves T cell function and promotes immune control of HPVbioRxiv : the preprint server for biology · 2026Article
- Pharmacological WEE1 inhibition as a strategy to overcome cisplatin resistance in non-seminoma testicular cancer: insights from preclinical models.Scientific reports · 2026Article
- Integrative pan-cancer analysis of dipeptidyl peptidase 4 with clinical andFrontiers in immunology · 2026Article
- Tumor-intrinsic and immune-related features associated with treatment failure in human papillomavirus-related oropharyngeal cancer.Journal of the National Cancer Institute · 2025Article
- Therapeutic potential of targeting the FLNA-regulated Wee1 kinase in adrenocortical carcinomas.International journal of cancer · 2025Article
- The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition.Frontiers in cell and developmental biology · 2025Review
- AZD1775 synergizes with SLC7A11 inhibition to promote ferroptosis.Science China. Life sciences · 2025Article
- Strategies to Overcome Intrinsic and Acquired Resistance to Chemoradiotherapy in Head and Neck Cancer.Cells · 2024Review
- Association of oropharyngeal cancer recurrence with tumor-intrinsic and immune-mediated sequelae of reduced genomic instability.bioRxiv : the preprint server for biology · 2024Article
- Functional RNAi Screening Identifies G2/M and Kinetochore Components as Modulators of TNFα/NF-κB Prosurvival Signaling in Head and Neck Squamous Cell Carcinoma.Cancer research communications · 2024Article
- Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.Targeted oncology · 2024Article
- Wee1 inhibitor PD0166285 sensitized TP53 mutant lung squamous cell carcinoma to cisplatin via STAT1.Cancer cell international · 2024Article
- Therapeutic Advances and Challenges for the Management of HPV-Associated Oropharyngeal Cancer.International journal of molecular sciences · 2024Review
- Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets.International journal of molecular sciences · 2024Review
- Results and lessons learnt from the WISTERIA phase I trial combining AZD1775 with cisplatin pre- or post-operatively in head and neck cancer.BJC reports · 2024Article
- Mucin-producing urothelial-type adenocarcinoma of the prostate with sarcomatoid features and novel molecular phenotype.IJU case reports · 2024Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Eduardo MéndezDepartment of Otolaryngology: Head and Neck Surgery, University of Washington, Seattle, Washington.
Cristina P RodriguezDepartment of Medicine, University of Washington, Seattle, Washington.
Michael C KaoDepartment of Otolaryngology: Head and Neck Surgery, University of Washington, Seattle, Washington.
Sharat RajuDepartment of Otolaryngology: Head and Neck Surgery, University of Washington, Seattle, Washington.
Ahmed DiabClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
R Alex HarbisonDepartment of Otolaryngology: Head and Neck Surgery, University of Washington, Seattle, Washington.
Eric Q KonnickDepartment of Laboratory Medicine, University of Washington, Seattle, Washington.ORCID 0000-0001-5904-1788
Ganesh M MugunduAstraZeneca, Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, Waltham, Massachusetts.
Rafael Santana-DavilaDepartment of Medicine, University of Washington, Seattle, Washington.
Renato MartinsDepartment of Medicine, University of Washington, Seattle, Washington.
Neal D FutranDepartment of Otolaryngology: Head and Neck Surgery, University of Washington, Seattle, Washington.
Laura Q M ChowDepartment of Medicine, University of Washington, Seattle, Washington. lchow@seattlecca.org.
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4MResearch Training in OtolaryngologyT32DC000018 · NIDCD · UNIVERSITY OF WASHINGTON · PI STONE, JENNIFER S. · 1989 to 2023
$7.8MPersonalized cancer models to discover and develop new therapeutic targets.U01CA217883 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KEMP, CHRISTOPHER J · 2017 to 2021
$4.3MAn integrated computational and functional genomics discovery engine for precliniU01CA176303 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KEMP, CHRISTOPHER J · 2013 to 2016
$4.1MAn Academic-Industry Partnership to Advance Functional Genomics for Personalized Oncology.R01CA214428 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KEMP, CHRISTOPHER J · 2018 to 2022
$3.0MExploiting WEE1/p53 synthetic lethality as a novel therapy in head and neck cancerR01CA215647 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CLURMAN, BRUCE E, KEMP, CHRISTOPHER J · 2017 to 2021
$2.0MNCI NIH HHS P30 CA015704NCI NIH HHS R01 CA214428NCI NIH HHS R01 CA215647NCI NIH HHS U01 CA176303NCI NIH HHS U01 CA217883NIDCD NIH HHS T32 DC000018
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsBiomarkersBiopsyCisplatinDocetaxelDrug Administration ScheduleFemaleGene Expression ProfilingGenomicsHumansMaleNeoadjuvant TherapyPositron-Emission TomographyPyrazolesPyrimidinonesSquamous Cell Carcinoma of Head and NeckadavosertibBiomarkersCisplatinDocetaxelPyrazolesPyrimidinones
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.